Insulin pump therapy in type 1 diabetes mellitus: education effectiveness and quality of life
https://doi.org/10.14341/2072-0351-5977
Abstract
Aim.
To compare efficacy of special structured program for type 1 diabetes mellitus (DM) group education between users of an integratedreal-time (RT) continuous glucose monitoring (CGM)/continuous subcutaneous insulin infusion (CSII) systems and patientson CSII and self-monitoring of blood glucose (SMBG).Methods.
This 4 months trial included 39 adults (18 male, age 27 [24,0;35,0] years) with type 1 DM (duration of diabetes 12[8,0;18,0] years). All subjects were randomized to study groups: 20 in the CSII/SMBG arm and 19 in the RT-CGM/CSII arm. Allparticipants were provided with special structured program for group education of diabetes patients on insulin pump therapy. Qualityof life (QoL) was assessed with questionnaire SF-36.
Results.
Both groups were not significantly different in HbA1c, BMI and QoL at baseline. After 4 months HbA1c was significantly lowerin both study groups without increase in rate of hypoglycemia. Improvements in QoL were observed in psychic health score in the CSII/SMBG arm and in physical health and psychic health scores in the RT-CGM/CSII arm. There was no significant difference in HbA1c,BMI and QoL between groups.
Conclusion.
Transfer to CSII during group training under special structured program for patients with type 1 DM significantly improvesglycemic control regardless of glucose monitoring method. Both RT-CGM+CSII and SMBG+CSII amend several aspects of QoL.Finally, transfer to CSII during group training considerably reduces total consumption of trainers time without loss of training quality.
To compare efficacy of special structured program for type 1 diabetes mellitus (DM) group education between users of an integratedreal-time (RT) continuous glucose monitoring (CGM)/continuous subcutaneous insulin infusion (CSII) systems and patientson CSII and self-monitoring of blood glucose (SMBG).Methods.
This 4 months trial included 39 adults (18 male, age 27 [24,0;35,0] years) with type 1 DM (duration of diabetes 12[8,0;18,0] years). All subjects were randomized to study groups: 20 in the CSII/SMBG arm and 19 in the RT-CGM/CSII arm. Allparticipants were provided with special structured program for group education of diabetes patients on insulin pump therapy. Qualityof life (QoL) was assessed with questionnaire SF-36.
Results.
Both groups were not significantly different in HbA1c, BMI and QoL at baseline. After 4 months HbA1c was significantly lowerin both study groups without increase in rate of hypoglycemia. Improvements in QoL were observed in psychic health score in the CSII/SMBG arm and in physical health and psychic health scores in the RT-CGM/CSII arm. There was no significant difference in HbA1c,BMI and QoL between groups.
Conclusion.
Transfer to CSII during group training under special structured program for patients with type 1 DM significantly improvesglycemic control regardless of glucose monitoring method. Both RT-CGM+CSII and SMBG+CSII amend several aspects of QoL.Finally, transfer to CSII during group training considerably reduces total consumption of trainers time without loss of training quality.
About the Authors
Lyudmila Ibragimovna Ibragimova
Endocrinology Research Centre, Moscow
Yury Ivanovich Filippov
Endocrinology Research Centre, Moscow
Alexander Yur'evich Mayorov
Endocrinology Research Centre, Moscow
References
1. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003 Apr;26(4):1079-1087.
2. Barnard K, Lloyd C, Skinner T. Systematic literature review: quality of life associated with insulin pump use in type 1 diabetes. Diabet Med. 2007 Jun;24(6):607-617.
3. Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103.
4. Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther. 2008 Oct;10(5):377-383.
5. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008 Oct 2;359(14):1464-1476.
6. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006 Jan;29(1):44-50.
7. Rubin RR, Peyrot M. Treatment Satisfaction and Quality of Life for an Integrated Continuous Glucose Monitoring/Insulin Pump System Compared to Self-Monitoring Plus an Insulin Pump. J Diabetes Sci Technol. 2009 Nov 1;3(6):1402-1410.
8. Hermanides J, Nørgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan C.M, Diem P, Fermon C, Wentholt I.M, Hoekstra J.B, DeVries J.H. Sensor augmented pump therapy substantially lowers HbA1c: a randomized controlled trial [abstract] Diabetologia. 2009;52(Suppl 1):S43.
9. Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, Jeandidier N, Nicolino M. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care. 2009 Dec;32(12):2245-2250.
10. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией Дедова ИИ, Шестаковой МВ. 5-й выпуск. М., 2011.
11. Шишкова ЮА, Мотовилин ОГ, Дивисенко СИ, Суркова ЕВ, Майоров АЮ. Качество жизни больных сахарным диабетом 1 типа молодого возраста. Сахарный диабет. 2010;(4):43-47.
12. Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care. 1994 Apr;17(4):267-274.
13. Старостина ЕГ. Биомедицинские и психосоциальные аспекты сахарного диабета и ожирения: взаимодействие врача и пациента и пути его оптимизации. Автореф. дисс. д.м.н. М, 2003.
14. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA, for the STAR 3 Study Group*. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. N Engl J Med. 2010 Jul 22;363(4):311-20.
15. Инструкция по обработке данных, полученных с помощью опросника SF-36 [Интернет-источник]. Доступно по ссылке: http://webmed.irkutsk.ru/doc/pdf/sf36.pdf
Review
For citations:
Ibragimova L.I., Filippov Yu.I., Mayorov A.Yu. Insulin pump therapy in type 1 diabetes mellitus: education effectiveness and quality of life. Diabetes mellitus. 2012;15(1):35-40. (In Russ.) https://doi.org/10.14341/2072-0351-5977
Views:
840
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
